{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T22:17:00Z","timestamp":1755037020062,"version":"3.37.3"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC-111-2218-E 008-009"],"award-info":[{"award-number":["NSTC-111-2218-E 008-009"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Angiotensin receptor blockers (ARBs) are considered an alternative to angiotensin-converting enzyme inhibitors (ACEIs) in patients with acute myocardial infarction (AMI), but in the era of extensive use of preventive therapies and percutaneous coronary intervention, this has not been adequately evaluated in Asians.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This retrospective cohort study used data from the Taiwan National Health Insurance Research Database. In total, 52,620 patients initially hospitalized due to AMI between 2002 and 2015 were assessed.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>After propensity score matching, 14,993 patients each were assigned to ACEI and ARB groups. Patients who received ARBs had significantly lower all-cause mortality (adjusted hazard ratio [aHR]: 0.82; 95% confidence interval [CI]: 0.75\u20130.90) and hospitalization for heart failure (aHR: 0.92; 95% CI: 0.85\u20130.99) compared with those who received ACEIs at 18 month follow-up. No significant difference was observed between the two groups in terms of major adverse cardiovascular events (aHR: 098; 95% CI: 0.90\u20131.07), cardiovascular death (aHR: 0.82; 95% CI: 0.68\u20131.00), ischemia stroke (aHR: 0.93; 95% CI: 0.77\u20131.11), and nonfatal myocardial infarction (aHR: 1.04; 95% CI: 0.93\u20131.17). ARBs showed benefits in many subgroups in terms of all-cause mortality and cardiovascular death.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Real-world data demonstrate that ARBs might be associated with lower all-cause mortality and hospitalization for heart failure compared with ACEIs among patients with AMI.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0290251","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T17:36:02Z","timestamp":1694712962000},"page":"e0290251","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of clinical outcomes of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1249-5699","authenticated-orcid":true,"given":"Chih-Wei","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3168-082X","authenticated-orcid":true,"given":"Chun-Wei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3599-7758","authenticated-orcid":true,"given":"Yi-Cheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Nien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8978-7879","authenticated-orcid":true,"given":"Chun-Yao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"issue":"1","key":"pone.0290251.ref001","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/ccd.24776","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions","volume":"82","author":"PT O\u2019Gara","year":"2013","journal-title":"Catheter Cardiovasc Interv"},{"issue":"2","key":"pone.0290251.ref002","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"B Ibanez","year":"2018","journal-title":"Eur Heart J"},{"issue":"6","key":"pone.0290251.ref003","first-page":"544","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"74","author":"JP Collet","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"pone.0290251.ref004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40885-016-0042-0","article-title":"A review on prescribing patterns of antihypertensive drugs","volume":"22","author":"N Jarari","year":"2015","journal-title":"Clin Hypertens"},{"issue":"11","key":"pone.0290251.ref005","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/ejhf.887","article-title":"Physicians\u2019 guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"19","author":"M Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"pone.0290251.ref006","article-title":"Patterns of use of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers among patients with acute myocardial infarction in China from 2001 to 2011: China PEACE-Retrospective AMI Study","volume":"4","author":"J Liu","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"pone.0290251.ref007","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3904\/kjim.2014.268","article-title":"Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction","volume":"31","author":"JH Lee","year":"2016","journal-title":"Korean J Intern Med"},{"issue":"8906","key":"pone.0290251.ref008","first-page":"1115","article-title":"GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019infarto Miocardico","volume":"343","year":"1994","journal-title":"Lancet"},{"issue":"8951","key":"pone.0290251.ref009","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(95)90865-X","article-title":"ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group","volume":"345","year":"1995","journal-title":"Lancet"},{"issue":"9348","key":"pone.0290251.ref010","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/S0140-6736(02)11745-4","article-title":"The OPTIMAAL trial: losartan or captopril after acute myocardial infarction","volume":"360","author":"Optimal Trial in Myocardial Infarction with the Angiotensin IIAL","year":"2002","journal-title":"Lancet"},{"issue":"20","key":"pone.0290251.ref011","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"MA Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0290251.ref012","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"GL Bakris","year":"2000","journal-title":"Archives of internal medicine"},{"issue":"12","key":"pone.0290251.ref013","first-page":"1681","article-title":"Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with outcomes after acute kidney injury","volume":"178","author":"S Brar","year":"2018","journal-title":"JJim"},{"issue":"22","key":"pone.0290251.ref014","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/CIRCULATIONAHA.117.026112","article-title":"Angiotensin Receptor Blockers Do Not Reduce Risk of Myocardial Infarction, Cardiovascular Death, or Total Mortality: Further Evidence for the ARB-MI Paradox","volume":"135","author":"MH Strauss","year":"2017","journal-title":"Circulation"},{"issue":"22","key":"pone.0290251.ref015","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/01.CIR.97.22.2202","article-title":"Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group","volume":"97","year":"1998","journal-title":"Circulation"},{"key":"pone.0290251.ref016","doi-asserted-by":"crossref","first-page":"d2234","DOI":"10.1136\/bmj.d2234","article-title":"Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials","volume":"342","author":"S Bangalore","year":"2011","journal-title":"BMJ"},{"issue":"9335","key":"pone.0290251.ref017","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial","volume":"360","author":"OSGJT","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"pone.0290251.ref018","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2012.10.011","article-title":"A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure","volume":"61","author":"G Savarese","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"pone.0290251.ref019","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","article-title":"Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials","volume":"91","author":"S Bangalore","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"pone.0290251.ref020","first-page":"1074248418795897","article-title":"Angiotensin-Converting Enzyme Inhibitors Provide Better Long-Term Survival Benefits to Patients With AMI Than Angiotensin II Receptor Blockers After Survival Hospital Discharge","author":"IS Choi","year":"2018","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"pone.0290251.ref021","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40256-019-00326-8","article-title":"Clinical Outcomes at 2 Years Between Beta-Blockade with ACE Inhibitors or ARBs in Patients with AMI Who Underwent Successful PCI with DES: A Retrospective Analysis of 23,978 Patients in the Korea AMI Registry","volume":"19","author":"YH Kim","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"pone.0290251.ref022","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2018.11.030","article-title":"Impact of renin-angiotensin system inhibitors on long-term clinical outcomes in patients with acute myocardial infarction treated with successful percutaneous coronary intervention with drug-eluting stents: Comparison between STEMI and NSTEMI","volume":"280","author":"YH Kim","year":"2019","journal-title":"Atherosclerosis"},{"issue":"3","key":"pone.0290251.ref023","doi-asserted-by":"crossref","first-page":"e0281460","DOI":"10.1371\/journal.pone.0281460","article-title":"Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction","volume":"18","author":"JG Lee","year":"2023","journal-title":"PLoS One"},{"issue":"2","key":"pone.0290251.ref024","doi-asserted-by":"crossref","first-page":"183.e11","DOI":"10.1016\/j.amjmed.2009.06.032","article-title":"Angiotensin-converting enzyme-related cough among Chinese-Americans","volume":"123","author":"DS Tseng","year":"2010","journal-title":"Am J Med"},{"issue":"14","key":"pone.0290251.ref025","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jacc.2016.01.050","article-title":"Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction","volume":"67","author":"M Evans","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"No. 2","key":"pone.0290251.ref026","first-page":"65","article-title":"Incidence and Prevalence of ESRD in Taiwan Renal Registry Data System (TWRDS): 2005\u20132012","volume":"Vol. 28","author":"Y-C Lin","year":"2014","journal-title":"Acta Nephrologica"},{"issue":"2","key":"pone.0290251.ref027","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1681\/ASN.2020050682","article-title":"Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study","volume":"32","author":"EL Fu","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"pone.0290251.ref028","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0895-4356(96)00268-5","article-title":"The assessment of refill compliance using pharmacy records: methods, validity, and applications","volume":"50","author":"JF Steiner","year":"1997","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"pone.0290251.ref029","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/HJH.0000000000000804","article-title":"Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study","volume":"34","author":"CJ Shih","year":"2016","journal-title":"J Hypertens"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0290251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T17:36:45Z","timestamp":1694713005000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0290251"}},"subtitle":[],"editor":[{"given":"Timir","family":"Paul","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0290251","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2023,9,14]]}}}